Logo

Lilly Reports Results of Taltz (ixekizumab) in P-III COAST-X Study for Non-Radiographic Axial Spondyloarthritis

Share this

Lilly Reports Results of Taltz (ixekizumab) in P-III COAST-X Study for Non-Radiographic Axial Spondyloarthritis

Shots:

  • The P-III COAST-X study involves assessing of Taltz (ixekizumab) vs PBO in patients with non-radiographic axial spondyloarthritis (nr-axSpA) who are biologic disease-modifying anti-rheumatic drug (bDMARD) naive for 52wks.
  • The P-III COAST-X study results:  @16 & 52wks. met its 1Eps & 2Eps; improvement in the signs and symptoms of nr-axSpA; improvement in ASDAS & BASDAI; patients achieve low disease activity (ASDAS <2.1); improvement in SIJ; improvement in SF-36 Physical Component Summary (PCS) score; no new safety signals observed
  • Taltz (ixekizumab) is a mAb- targeting interleukin 17A (IL-17A) cytokine by inhibiting its interaction with the IL-17 receptor and is under FDA review for radiographic axSpA with its expected regulatory action in H2’19

Ref: Eli Lilly | Image: Fortune

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions